Zenas Biopharma, Inc. (ZBIO) Stock Price & Analysis
Zenas Biopharma, Inc. (ZBIO) fell 0.12% to USD 32.88 as of September 8, 2026 at 05:49 UTC, according to Nexqual real-time market data.
ZBIO last closed at USD 32.88; the session ranged USD 32.38–33.29 on volume of 452,691 shares. Market capitalization is —, with a 52-week range of USD 13.5–44.6 (NMS). Source: Nexqual, September 8, 2026 at 05:49 UTC.
Key Statistics (as of September 8, 2026 at 05:49 UTC)
| Price | USD 32.88 |
|---|---|
| Change | ▼ 0.12% (down) |
| Previous Close | USD 32.88 |
| Open | USD 32.88 |
| Day Range | USD 32.38 – 33.29 |
| 52-Week Range | USD 13.5 – 44.6 |
| Volume | 452,691 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ZBIO)
Nexqual's technical model rates ZBIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.44 (neutral) |
| vs SMA50 | Above (USD 30.59) |
| MACD | 0.74 (positive) |
From Zenas Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- We also intend to submit a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") in the second half of 2026.
Partnerships
- In addition, in October 2024, we entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), under which we transferred to Tenacia our rights and obligations under our agreements with Dianthus Therapeutics Inc. ("Dianthus") for ZB005 (the "Tenacia Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 61.72 | ▲ 1.36% |
| BCAX | Bicara Therapeutics Inc. | USD 23.17 | ▼ 1.66% |
| UPB | Upstream Bio, Inc. | USD 6.01 | ▼ 7.25% |
| ALMS | Alumis Inc. | USD 11.1 | ▲ 7.25% |
| RAPP | Rapport Therapeutics, Inc. | USD 45.77 | ▼ 6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:49 UTC. This page is informational and not investment advice.